As diagnoses of Attention Deficit/Hyperactivity Disorder (ADHD) continue to increase among children and adolescents, new treatment options are emerging to address the condition’s impact on daily life. Methylphenidate, a commonly prescribed stimulant, is now available in a chewable tablet formulation designed for patients aged 6-17, offering a possibly more convenient delivery method [[1]]. This new formulation joins other methylphenidate options aimed at improving focus and reducing impulsive behaviors associated with ADHD [[2]].
Children and adolescents with Attention Deficit/Hyperactivity Disorder (ADHD) now have a new medication option, offering a delayed-release formulation of methylphenidate. This expanded choice comes as ADHD diagnoses continue to rise, impacting learning, behavior, and overall well-being for millions of young people.
Understanding the New Formulation
Currently, methylphenidate, a commonly prescribed medication for ADHD, is primarily available in immediate-release forms like tablets, extended-release tablets, and capsules, as well as a liquid solution. Now, a new chewable tablet is available in three strengths – 20mg, 30mg, and 40mg – designed for children and adolescents between the ages of 6 and 17. The medication is intended for use as part of a comprehensive treatment plan when other approaches haven’t provided sufficient relief.
The chewable tablets are designed to be taken once daily and must be thoroughly chewed before swallowing. They should not be swallowed whole or crushed. The 20mg and 30mg tablets include a score line, allowing for flexible dosage adjustments. The medication can be taken without water.
According to the manufacturer, the new formulation aims to provide quick and sustained symptom control for up to eight hours. It utilizes a two-phase release system: 30% of the medication is released immediately, providing effects within 45 minutes, while the remaining 70% is released over a longer period. Clinical trials evaluating the medication reported that adverse events were not more frequent than those observed with a placebo.
The medication is approved for use in individuals diagnosed with Attention Deficit/Hyperactivity Disorder (ADHD), and is intended to be used alongside other therapies. More information about methylphenidate can be found online.
